Pub Date : 2021-12-09DOI: 10.1080/00940798.2021.2009708
Kae Bara Kratcha
(2022). MEDIA REVIEW. The Oral History Review: Vol. 49, No. 1, pp. 137-139.
(2022)。媒体审查。口述历史评论:第49卷，第1期，137-139页。
{"title":"MEDIA REVIEW","authors":"Kae Bara Kratcha","doi":"10.1080/00940798.2021.2009708","DOIUrl":"https://doi.org/10.1080/00940798.2021.2009708","url":null,"abstract":"(2022). MEDIA REVIEW. The Oral History Review: Vol. 49, No. 1, pp. 137-139.","PeriodicalId":44122,"journal":{"name":"Oral History Review","volume":"8 1","pages":""},"PeriodicalIF":1.1,"publicationDate":"2021-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138537213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"历史学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-08-31DOI: 10.1080/00940798.2021.1957306
(2021). Editors’ Introduction. The Oral History Review: Vol. 48, Ethics in Oral History, pp. 133-135.
(2021)。编辑的介绍。《口述历史评论》第48卷，《口述历史中的伦理》，第133-135页。
{"title":"Editors’ Introduction","authors":"","doi":"10.1080/00940798.2021.1957306","DOIUrl":"https://doi.org/10.1080/00940798.2021.1957306","url":null,"abstract":"(2021). Editors’ Introduction. The Oral History Review: Vol. 48, Ethics in Oral History, pp. 133-135.","PeriodicalId":44122,"journal":{"name":"Oral History Review","volume":"2 1","pages":""},"PeriodicalIF":1.1,"publicationDate":"2021-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138537192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"历史学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.17925/ohr.2020.16.1.31
S. Armstrong, Rita Malley, B. Weinberg
BRAF V600E-mutated metastatic colorectal cancer is notoriously difficult to treat due to an aggressive tumor biology and resistance to chemotherapy. Single-agent BRAF inhibition has proven ineffective in this patient population. Approaches combining BRAF with epidermal growth factor receptor and mitogen-activated extracellular signal-regulated kinase inhibition are effective in overcoming resistance to BRAF monotherapy, and this treatment combination provides a superior overall survival benefit compared with irinotecan-based chemotherapy. Encorafenib plus cetuximab is now a US Food and Drug Administration-approved treatment option for patients with BRAF V600E-mutated metastatic colorectal cancer after prior therapy. Ongoing clinical trials using immunotherapy and other targeted agents aim to further improve on these outcomes. We highlight the epidemiology and mutational landscape of BRAF-mutated colorectal cancer, as well as novel treatment options for patients with this subtype of metastatic colorectal cancer.
{"title":"Glimmers of Hope—New Strategies for Overcoming Treatment Resistance in Patients with BRAF V600E-mutated Metastatic Colorectal Cancer","authors":"S. Armstrong, Rita Malley, B. Weinberg","doi":"10.17925/ohr.2020.16.1.31","DOIUrl":"https://doi.org/10.17925/ohr.2020.16.1.31","url":null,"abstract":"BRAF V600E-mutated metastatic colorectal cancer is notoriously difficult to treat due to an aggressive tumor biology and resistance to chemotherapy. Single-agent BRAF inhibition has proven ineffective in this patient population. Approaches combining BRAF with epidermal growth factor receptor and mitogen-activated extracellular signal-regulated kinase inhibition are effective in overcoming resistance to BRAF monotherapy, and this treatment combination provides a superior overall survival benefit compared with irinotecan-based chemotherapy. Encorafenib plus cetuximab is now a US Food and Drug Administration-approved treatment option for patients with BRAF V600E-mutated metastatic colorectal cancer after prior therapy. Ongoing clinical trials using immunotherapy and other targeted agents aim to further improve on these outcomes. We highlight the epidemiology and mutational landscape of BRAF-mutated colorectal cancer, as well as novel treatment options for patients with this subtype of metastatic colorectal cancer.","PeriodicalId":44122,"journal":{"name":"Oral History Review","volume":"16 1","pages":"31"},"PeriodicalIF":1.1,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67597481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"历史学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.17925/ohr.2020.16.1.23
N. McAndrew, Kelly E McCann
Systemic therapy for advanced, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-unamplified (HER2-) breast cancer has drastically evolved over the past several decades, from oophorectomy to combination endocrine and molecularly targeted therapy. Cyclin-dependent kinase (CDK) 4/6 inhibitors are the latest addition to this arsenal of therapies, and while they have been rapidly adopted by most oncologists, many still question whether they belong in the first-line metastatic setting. Recent reporting of overall survival data, however, has re-invigorated the debate and strongly supports first-line use of CDK 4/6 inhibitors. This article will provide an overview of the evolution of systemic therapy in HR+, HER2breast cancer, summarize the data that led to the approval of CDK 4/6 inhibitors, detail the new overall survival data reported in the PALOMA-3, MONALEESA-7, MONALEESA-3, and MONARCH-2 trials, and then discuss why our patients should receive these drugs in the first-line setting for advanced disease.
{"title":"Why CDK 4/6 Inhibitors are Practice Changing in Advanced Breast Cancer","authors":"N. McAndrew, Kelly E McCann","doi":"10.17925/ohr.2020.16.1.23","DOIUrl":"https://doi.org/10.17925/ohr.2020.16.1.23","url":null,"abstract":"Systemic therapy for advanced, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-unamplified (HER2-) breast cancer has drastically evolved over the past several decades, from oophorectomy to combination endocrine and molecularly targeted therapy. Cyclin-dependent kinase (CDK) 4/6 inhibitors are the latest addition to this arsenal of therapies, and while they have been rapidly adopted by most oncologists, many still question whether they belong in the first-line metastatic setting. Recent reporting of overall survival data, however, has re-invigorated the debate and strongly supports first-line use of CDK 4/6 inhibitors. This article will provide an overview of the evolution of systemic therapy in HR+, HER2breast cancer, summarize the data that led to the approval of CDK 4/6 inhibitors, detail the new overall survival data reported in the PALOMA-3, MONALEESA-7, MONALEESA-3, and MONARCH-2 trials, and then discuss why our patients should receive these drugs in the first-line setting for advanced disease.","PeriodicalId":44122,"journal":{"name":"Oral History Review","volume":"16 1","pages":"23"},"PeriodicalIF":1.1,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67597468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"历史学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.17925/ohr.2020.16.1.15
B. V. Tine
Support: No funding was received in the publication of this article. Soft tissue sarcomas represent a group of over 80 rare malignant tumors that arise from tissues of mesenchymal origin throughout the body. Advanced soft tissue sarcoma is treated with single-agent or combination systemic chemotherapy, but is associated with a poor prognosis. Pazopanib (Votrient, Novartis, Basel, Switzerland) is an oral multitarget tyrosine kinase inhibitor that has received regulatory approval as a second-line and beyond treatment for metastatic soft tissue sarcoma based on the findings of the phase III PALETTE study (ClinicalTrials.gov identifier: NCT00753688). However, there is a population of elderly and debilitated patients with soft tissue sarcoma who are not fit for standard first-line chemotherapy that is anthracycline-based. As pazopanib is well tolerated with minimal side effects, a phase II study (ClinicalTrials.gov identifier: NCT02300545) investigated the use of pazopanib as front-line therapy in patients with non-resectable or metastatic soft tissue sarcomas who are not candidates for chemotherapy.
{"title":"Pazopanib in Soft Tissue Sarcomas","authors":"B. V. Tine","doi":"10.17925/ohr.2020.16.1.15","DOIUrl":"https://doi.org/10.17925/ohr.2020.16.1.15","url":null,"abstract":"Support: No funding was received in the publication of this article. Soft tissue sarcomas represent a group of over 80 rare malignant tumors that arise from tissues of mesenchymal origin throughout the body. Advanced soft tissue sarcoma is treated with single-agent or combination systemic chemotherapy, but is associated with a poor prognosis. Pazopanib (Votrient, Novartis, Basel, Switzerland) is an oral multitarget tyrosine kinase inhibitor that has received regulatory approval as a second-line and beyond treatment for metastatic soft tissue sarcoma based on the findings of the phase III PALETTE study (ClinicalTrials.gov identifier: NCT00753688). However, there is a population of elderly and debilitated patients with soft tissue sarcoma who are not fit for standard first-line chemotherapy that is anthracycline-based. As pazopanib is well tolerated with minimal side effects, a phase II study (ClinicalTrials.gov identifier: NCT02300545) investigated the use of pazopanib as front-line therapy in patients with non-resectable or metastatic soft tissue sarcomas who are not candidates for chemotherapy.","PeriodicalId":44122,"journal":{"name":"Oral History Review","volume":"16 1","pages":"15"},"PeriodicalIF":1.1,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67597413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"历史学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.17925/ohr.2020.16.1.36
K. Ciombor, T. Bekaii-Saab
{"title":"Precision Medicine in Metastatic Colorectal Cancer—Finding and Hitting the Right Targets","authors":"K. Ciombor, T. Bekaii-Saab","doi":"10.17925/ohr.2020.16.1.36","DOIUrl":"https://doi.org/10.17925/ohr.2020.16.1.36","url":null,"abstract":"<p />","PeriodicalId":44122,"journal":{"name":"Oral History Review","volume":"60 4 1","pages":""},"PeriodicalIF":1.1,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67598014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"历史学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.17925/ohr.2020.16.1.12
P. Richardson
Support: No funding was received in the publication of this article. Multiple myeloma (MM) is the second most common hematological malignancy after non-Hodgkin’s lymphoma. Although recent decades have seen considerable advances and improvements in clinical outcomes for patients with MM, MM remains incurable, with a high disease burden. Clonal evolution and genomic instability within myeloma clones inevitably lead to disease progression and treatment resistance. An increasing number of patients are becoming refractory to multiple treatments; therefore, there is a need for new drugs with novel mechanisms of action.
{"title":"Melflufen—A Novel Agent in the Treatment of Relapsed/Refractory Multiple Myeloma","authors":"P. Richardson","doi":"10.17925/ohr.2020.16.1.12","DOIUrl":"https://doi.org/10.17925/ohr.2020.16.1.12","url":null,"abstract":"Support: No funding was received in the publication of this article. Multiple myeloma (MM) is the second most common hematological malignancy after non-Hodgkin’s lymphoma. Although recent decades have seen considerable advances and improvements in clinical outcomes for patients with MM, MM remains incurable, with a high disease burden. Clonal evolution and genomic instability within myeloma clones inevitably lead to disease progression and treatment resistance. An increasing number of patients are becoming refractory to multiple treatments; therefore, there is a need for new drugs with novel mechanisms of action.","PeriodicalId":44122,"journal":{"name":"Oral History Review","volume":"16 1","pages":"12"},"PeriodicalIF":1.1,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67597343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"历史学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.17925/ohr.2020.16.1.59
R. Sharman, R. Shroff
{"title":"Improving Outcomes in Pancreatic Cancer","authors":"R. Sharman, R. Shroff","doi":"10.17925/ohr.2020.16.1.59","DOIUrl":"https://doi.org/10.17925/ohr.2020.16.1.59","url":null,"abstract":"<p />","PeriodicalId":44122,"journal":{"name":"Oral History Review","volume":"3 1","pages":""},"PeriodicalIF":1.1,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67598102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"历史学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.17925/ohr.2020.16.1.52
Anuhya Kommalapati, James Yu, R. Kim
Journal Publication Date: August 6, 2020 Personalized medicine is the new-generation concept of managing cancer, which primarily focuses on the development of targeted therapies blocking specific cellular pathways that potentiate the tumorigenesis and identify people that respond best. The combination of gemcitabine and a platinum agent, remains the first-line therapy in advanced cholangiocarcinoma. Thus far, there are no specific guidelines on the next step in the care of patients who progressed on, or could not tolerate, the first-line therapy. However, a better knowledge of molecular pathogenesis and advancements in the development of targeted therapy offers hope that we may improve outcomes in advanced cholangiocarcinoma. Among the newly discovered molecular alterations, targeting isocitrate dehydrogenase (IDH1/2) mutations, fibroblast growth factor receptor 2 (FGFR2) fusions, RAS-MAPK pathway activation, BRCA1/2 mutations, NTRK fusions, and human epidermal growth factor receptor 2 (HER2), hold great promise for improving the future management of cholangiocarcinoma. In tumors with high microsatellite instabilities or mismatch repair deficiencies irrespective of programmed death ligand (PD-L) 1 expression, immunotherapy, alone or in combination with targeted agents and chemotherapy, are currently being evaluated. This review article details the potential targetable molecular pathways and future directions in implementing personalized medicine in this dismal cancer.
{"title":"Personalized Medicine in Advanced Cholangiocarcinoma","authors":"Anuhya Kommalapati, James Yu, R. Kim","doi":"10.17925/ohr.2020.16.1.52","DOIUrl":"https://doi.org/10.17925/ohr.2020.16.1.52","url":null,"abstract":"Journal Publication Date: August 6, 2020 Personalized medicine is the new-generation concept of managing cancer, which primarily focuses on the development of targeted therapies blocking specific cellular pathways that potentiate the tumorigenesis and identify people that respond best. The combination of gemcitabine and a platinum agent, remains the first-line therapy in advanced cholangiocarcinoma. Thus far, there are no specific guidelines on the next step in the care of patients who progressed on, or could not tolerate, the first-line therapy. However, a better knowledge of molecular pathogenesis and advancements in the development of targeted therapy offers hope that we may improve outcomes in advanced cholangiocarcinoma. Among the newly discovered molecular alterations, targeting isocitrate dehydrogenase (IDH1/2) mutations, fibroblast growth factor receptor 2 (FGFR2) fusions, RAS-MAPK pathway activation, BRCA1/2 mutations, NTRK fusions, and human epidermal growth factor receptor 2 (HER2), hold great promise for improving the future management of cholangiocarcinoma. In tumors with high microsatellite instabilities or mismatch repair deficiencies irrespective of programmed death ligand (PD-L) 1 expression, immunotherapy, alone or in combination with targeted agents and chemotherapy, are currently being evaluated. This review article details the potential targetable molecular pathways and future directions in implementing personalized medicine in this dismal cancer.","PeriodicalId":44122,"journal":{"name":"Oral History Review","volume":"16 1","pages":"52"},"PeriodicalIF":1.1,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67598025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"历史学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"First days project. Website, South Asian American Digital Archive, with volunteer reporters and interviewers, and partner organizations, info@firstdaysproject.org. https://www.firstdaysproject.org/.","authors":"C. Niemeyer","doi":"10.1093/ohr/ohz016","DOIUrl":"https://doi.org/10.1093/ohr/ohz016","url":null,"abstract":"","PeriodicalId":44122,"journal":{"name":"Oral History Review","volume":"46 1","pages":"435 - 436"},"PeriodicalIF":1.1,"publicationDate":"2019-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/ohr/ohz016","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61387548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"历史学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：